Preventive Treatment of Episodic Migraine with CGRP-Blocking Antibodies

A phase 3, randomized, controlled trial demonstrates that galcanezumab treatment is effective in reducing migraine frequency and has a favorable safety profile.

Phase 2 trials have shown that blocking calcitonin gene-related peptide (CGRP) with the humanized monoclonal antibody (mAb) galcanezumab is effective in the preventive treatment of migraine. To further assess the efficacy of galcanezumab in a larger patient population, the drug was tested in a manufacturer-sponsored, phase 3, randomized, controlled trial.

Participants received one of two dosing regimens of galcanezumab (120 mg and 240 mg, injected subcutaneously) or placebo monthly for 6 months. The 862 participants fulfilled criteria for episodic migraine of 4 to 14 migraine headache days per month, and no other preventive medications were allowed. Patients who had not responded to previous migraine preventive treatment were excluded.

Compar…

Reviewing Author

Sabrina Khan, MD

Preventive Treatment of Episodic Migraine with CGRP-Blocking Antibodies

Topics

Reviewing Author